AllianceBernstein
NRIX icon

AllianceBernstein’s Nurix Therapeutics NRIX Stock Holding History

AllianceBernstein’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72M Buy
111,290
+13,100
+13% +$223K ﹤0.01% 2125
2026
Q1 		$1.86M Hold
98,190
– – ﹤0.01% 2048
2025
Q4 		$1.86M Buy
98,190
+34,870
+55% +$501K ﹤0.01% 2039
2025
Q3 		$585K Hold
63,320
– – ﹤0.01% 2595
2025
Q2 		$721K Hold
63,320
– – ﹤0.01% 2458
2025
Q1 		$752K Hold
63,320
– – ﹤0.01% 2376
2024
Q4 		$1.19M Hold
63,320
– – ﹤0.01% 2242
2024
Q3 		$1.42M Hold
63,320
– – ﹤0.01% 2145
2024
Q2 		$1.32M Buy
63,320
+16,860
+36% +$263K ﹤0.01% 2167
2024
Q1 		$683K Hold
46,460
– – ﹤0.01% 2449
2023
Q4 		$479K Hold
46,460
– – ﹤0.01% 2627
2023
Q3 		$365K Sell
46,460
-75,000
-62% -$685K ﹤0.01% 2731
2023
Q2 		$1.21M Buy
121,460
+85,160
+235% +$868K ﹤0.01% 2173
2023
Q1 		$322K Sell
36,300
-126,600
-78% -$1.32M ﹤0.01% 2745
2022
Q4 		$1.79M Buy
162,900
+80,000
+97% +$965K ﹤0.01% 1988
2022
Q3 		$1.08M Buy
82,900
+9,639
+13% +$153K ﹤0.01% 2245
2022
Q2 		$928K Buy
73,261
+40,361
+123% +$457K ﹤0.01% 2390
2022
Q1 		$461K Buy
32,900
+100
+0.3% +$1.77K ﹤0.01% 2715
2021
Q4 		$950K Sell
32,800
-59,724
-65% -$1.81M ﹤0.01% 2487
2021
Q3 		$2.77M Buy
92,524
+59,724
+182% +$1.84M ﹤0.01% 1964
2021
Q2 		$870K Buy
+32,800
New +$963K ﹤0.01% 2598

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AllianceBernstein's NRIX Position: Q2 2026 in Review

AllianceBernstein increased its Nurix Therapeutics (NRIX) stake by 13% in Q2 2026, buying an estimated $223K and bringing the position to 111,290 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2125.

AllianceBernstein first reported a position in NRIX in Q2 2021 and has held it in 21 quarters since. The position peaked at $2.77M in Q3 2021. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • AllianceBernstein held 111,290 shares of Nurix Therapeutics worth $1.72M as of Q2 2026.
  • AllianceBernstein bought 13,100 Nurix Therapeutics shares in Q2 2026, an estimated $223K.
  • Nurix Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2125 holding.
  • AllianceBernstein first reported a position in Nurix Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • AllianceBernstein's Nurix Therapeutics position peaked at $2.77M in Q3 2021.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.